Table 2.
Top-ranked alleles in the HLA-WAS on the CHGE European cohort
| Allele | OR [95% CI]a | Raw p valueb | AFc | Controls usedd |
|---|---|---|---|---|
| B∗40:02 | 3.42 [1.5–7.7] | 0.005 | 0.016 | Severe + Critical |
| DPB1∗01:01 | 0.28 [0.1–0.8] | 0.007 | 0.042 | Severe + Critical |
| A∗23:01 | 2.5 [1.2–5.0] | 0.010 | 0.023 | Mild + Moderate |
| B∗49:01 | 2.26 [1.2–4.3] | 0.014 | 0.031 | Mild + Moderate |
| A∗03:01 | 1.66 [1.1–2.5] | 0.019 | 0.12 | Severe + Critical |
| DQA1∗01:02 | 1.54 [1.1–2.2] | 0.022 | 0.18 | Mild + Moderate |
| A∗30:02 | 2.46 [1.1–5.6] | 0.031 | 0.019 | Mild + Moderate |
| B∗57:01 | 0.47 [0.2–1.0] | 0.047 | 0.027 | Mild + Moderate |
| A∗68:02 | 3.53 [1.0–12.2] | 0.047 | 0.01 | Mild + Moderate |
| DPB1∗03:01 | 0.65 [0.4–1.0] | 0.049 | 0.093 | Mild + Moderate |
a
Odds ratio (OR) of being asymptomatic, i.e., OR >1 indicates that the allele is more frequent in asymptomatic individuals. CI = confidence interval.
b
Significance threshold after Bonferroni correction for multiple testing is 0.00044. Alleles shown are those with a raw p value <0.05.
c
Allele frequency (AF) is based on the frequency of the allele in the CHGE European cohort “All” analysis, which included the largest numbers of cases and controls.
d
For each allele, the top-ranked result across three sets of symptomatic patients in the CHGE European sample is given.